These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23631381)

  • 1. Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution.
    Beloqui A; Solinís MÁ; Delgado A; Evora C; Isla A; Rodríguez-Gascón A
    J Microencapsul; 2014; 31(1):1-8. PubMed ID: 23631381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol.
    Qi R; Li YZ; Chen C; Cao YN; Yu MM; Xu L; He B; Jie X; Shen WW; Wang YN; van Dongen MA; Liu GQ; Banaszak Holl MM; Zhang Q; Ke X
    J Control Release; 2015 Jul; 210():160-8. PubMed ID: 26003044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution of nanostructured lipid carriers: a tomographic study.
    Esposito E; Boschi A; Ravani L; Cortesi R; Drechsler M; Mariani P; Moscatelli S; Contado C; Di Domenico G; Nastruzzi C; Giganti M; Uccelli L
    Eur J Pharm Biopharm; 2015 Jan; 89():145-56. PubMed ID: 25497177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration.
    Gaba B; Fazil M; Ali A; Baboota S; Sahni JK; Ali J
    Drug Deliv; 2015; 22(6):691-700. PubMed ID: 24670099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery.
    Li H; Chen M; Su Z; Sun M; Ping Q
    Int J Pharm; 2016 Sep; 511(1):524-537. PubMed ID: 27452421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies.
    Jia L; Zhang D; Li Z; Duan C; Wang Y; Feng F; Wang F; Liu Y; Zhang Q
    Colloids Surf B Biointerfaces; 2010 Oct; 80(2):213-8. PubMed ID: 20621458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia.
    Shamma RN; Aburahma MH
    Int J Nanomedicine; 2014; 9():5449-60. PubMed ID: 25473283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanostructured lipid carriers with exceptional gastrointestinal stability and inhibition of P-gp efflux for improved oral delivery of tilmicosin.
    Zhang Q; Yang H; Sahito B; Li X; Peng L; Gao X; Ji H; Wang L; Jiang S; Guo D
    Colloids Surf B Biointerfaces; 2020 Mar; 187():110649. PubMed ID: 31767412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route.
    Gabal YM; Kamel AO; Sammour OA; Elshafeey AH
    Int J Pharm; 2014 Oct; 473(1-2):442-57. PubMed ID: 25062866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodistribution of Nanostructured Lipid Carriers (NLCs) after intravenous administration to rats: influence of technological factors.
    Beloqui A; Solinís MA; Delgado A; Evora C; del Pozo-Rodríguez A; Rodríguez-Gascón A
    Eur J Pharm Biopharm; 2013 Jun; 84(2):309-14. PubMed ID: 23461861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine.
    Su Z; Niu J; Xiao Y; Ping Q; Sun M; Huang A; You W; Sang X; Yuan D
    Mol Pharm; 2011 Oct; 8(5):1641-51. PubMed ID: 21770405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide.
    Zhang T; Chen J; Zhang Y; Shen Q; Pan W
    Eur J Pharm Sci; 2011 Jun; 43(3):174-9. PubMed ID: 21530654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethyl oleate-containing nanostructured lipid carriers improve oral bioavailability of trans-ferulic acid ascompared with conventional solid lipid nanoparticles.
    Zhang Y; Li Z; Zhang K; Yang G; Wang Z; Zhao J; Hu R; Feng N
    Int J Pharm; 2016 Sep; 511(1):57-64. PubMed ID: 27374194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Oral Absorption of Amisulpride Via a Nanostructured Lipid Carrier-Based Capsules: Development, Optimization Applying the Desirability Function Approach and In Vivo Pharmacokinetic Study.
    El Assasy AEI; Younes NF; Makhlouf AIA
    AAPS PharmSciTech; 2019 Jan; 20(2):82. PubMed ID: 30652198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanostructured lipid carriers as a delivery system of biochanin A.
    Wang Q; Cheng H; Zhou K; Wang L; Dong S; Wang D; Chen W
    Drug Deliv; 2013 Nov; 20(8):331-7. PubMed ID: 24111887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption.
    Zhou X; Zhang X; Ye Y; Zhang T; Wang H; Ma Z; Wu B
    Int J Pharm; 2015 Feb; 479(2):391-8. PubMed ID: 25556104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cysteine-Functionalized Nanostructured Lipid Carriers for Oral Delivery of Docetaxel: A Permeability and Pharmacokinetic Study.
    Fang G; Tang B; Chao Y; Xu H; Gou J; Zhang Y; Xu H; Tang X
    Mol Pharm; 2015 Jul; 12(7):2384-95. PubMed ID: 25974386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daidzein-loaded nanostructured lipid carriers-PLGA nanofibers for transdermal delivery.
    Song J; Fan X; Shen Q
    Int J Pharm; 2016 Mar; 501(1-2):245-52. PubMed ID: 26851353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanostructured lipid carriers (NLCs) for drug delivery and targeting.
    Fang CL; Al-Suwayeh SA; Fang JY
    Recent Pat Nanotechnol; 2013 Jan; 7(1):41-55. PubMed ID: 22946628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro characterization and growth inhibition effect of nanostructured lipid carriers for controlled delivery of methotrexate.
    Abdelbary G; Haider M
    Pharm Dev Technol; 2013; 18(5):1159-68. PubMed ID: 21958084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.